PAR AND SPECTRUM JOIN TO DISTRIBUTE GENERICS

APRIL 01, 2006

Spectrum Pharmaceuticals will begin distribution of generic drugs produced by Par Pharmaceutical under a new strategic alliance agreed to by the 2 companies. Under the agreement, Par will make an unspecified equity investment in Spectrum, and Spectrum will receive payments based on achievement of specified regulatory approvals that company officials believe to be worth over $10 million. Par will also provide financial and legal support for the ongoing patent challenge for sumatriptan injection—a migraine treatment originally developed by GlaxoSmithKline—and both companies will share profits resulting from the sale of the generic products.




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.